Celularity Inc., (CELU): Price and Financial Metrics


Celularity Inc., (CELU): $8.91

0.40 (+4.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CELU to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CELU Stock Price Chart Interactive Chart >

Price chart for CELU

CELU Price/Volume Stats

Current price $8.91 52-week high $13.40
Prev. close $8.51 52-week low $3.63
Day low $8.08 Volume 296,200
Day high $8.96 Avg. volume 270,789
50-day MA $9.23 Dividend yield N/A
200-day MA $7.03 Market Cap 1.23B

Celularity Inc., (CELU) Company Bio


Celularity Inc., a clinical stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies. The company is developing unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR, and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious diseases, and degenerative diseases. It also develops and manufactures biomaterials derived from the postpartum placenta. The company was founded in 2016 and is based in Florham Park, New Jersey.


CELU Latest News Stream


Event/Time News Detail
Loading, please wait...

CELU Latest Social Stream


Loading social stream, please wait...

View Full CELU Social Stream

Latest CELU News From Around the Web

Below are the latest news stories about Celularity Inc that investors may wish to consider to help them evaluate CELU as an investment opportunity.

Celularity: Killing Cancer One Placenta at a Time

Celularity (CELU) is a clinical-stage biotech company at the frontier of some of the world’s most cutting-edge cancer research. The company’s innovative use of placental tissue as material for its NK-cell and T-cell therapies may prove more effective and cost-efficient than alternative allogeneic sources, which have traditionally been limited to iPSC, umbilical cord blood and healthy-donor peripheral blood. Oppenheimer analyst Matthew Biegler is of the belief that allogeneic NK-cell and T-cell therapies are on their way to replacing autologous CAR-T, citing “improvements in scalability, accessibility, and performance.

Emily Hollander on TipRanks | February 22, 2022

Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab as a first-line treatment in advanced HER2/neu positive gastric and gastroesophageal junction cancer Fifth designation received by Celularity within twelve months f

Yahoo | February 15, 2022

C V Starr & Co Inc Buys Celularity Inc

New York, NY, based Investment company C V Starr & Co Inc (Current Portfolio) buys Celularity Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, C V Starr & Co Inc.

Yahoo | January 27, 2022

Starr International Co Inc Buys Celularity Inc, Sells Moderna Inc, AstraZeneca PLC, Johnson ...

Zug, V8, based Investment company Starr International Co Inc (Current Portfolio) buys Celularity Inc, sells Moderna Inc, AstraZeneca PLC, Johnson & Johnson during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Starr International Co Inc.

Yahoo | January 27, 2022

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

The FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The

Benzinga | January 18, 2022

Read More 'CELU' Stories Here

CELU Price Returns

1-mo -23.78%
3-mo 24.09%
6-mo 38.35%
1-year -12.04%
3-year N/A
5-year N/A
YTD 74.02%
2021 -53.45%
2020 10.55%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.489 seconds.